Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Published:2021-07 Issue:7 Volume:9 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Wang Xiaomeng¹²³⁴^ORCID,Cao Jie⁵,Du Weijiao⁶²⁷³⁴,Zhang Weihong⁶²⁷³⁴,Cao Shui⁶²⁷³⁴

Affiliation:

1. Department of Comprehensive Medical Oncology Tianjin Medical University Cancer Institute and Hospital Tianjin China

2. National Clinical Research Center for Cancer Tianjin China

3. Tianjin's Clinical Research Center for Cancer Tianjin China

4. Key Laboratory of Cancer Prevention and Therapy Tianjin China

5. Wake Forest University Winston‐Salem NC USA

6. Department of Biotherapy Tianjin Medical University Cancer Institute and Hospital Tianjin China

7. Key Laboratory of Cancer Immunology and Biotherapy Tianjin China

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.4487

Reference21 articles.

1. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases

2. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Sarcomatoid Carcinoma of the Lung: Histologic Criteria and Common Lesions in the Differential Diagnosis

5. Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review;Translational Lung Cancer Research;2024-03

2. Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation;Frontiers in Oncology;2024-02-06

3. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-08-23

4. Targeted therapy for rare lung cancers: Status, challenges, and prospects;Molecular Therapy;2023-07

5. Advances in Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma;Advances in Clinical Medicine;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3